CD4 and neoplasm: The number of CD4+ and CD8+ TILs or their CD4/CD8 ratio did not vary significantly according to age, sex, tumor site, surgery type, relapse, MGMT promoter methylation, 1p/19q co-deletion, IDH1, and TP53 mutations.